These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30071276)

  • 1. Animal models for cystic fibrosis liver disease (CFLD).
    Fiorotto R; Amenduni M; Mariotti V; Cadamuro M; Fabris L; Spirli C; Strazzabosco M
    Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):965-969. PubMed ID: 30071276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota.
    Fiorotto R; Strazzabosco M
    Cell Mol Gastroenterol Hepatol; 2019; 8(2):197-207. PubMed ID: 31075352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Treatment Options for Cystic Fibrosis-Related Liver Disease.
    Staufer K
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver disease in cystic fibrosis.
    Rowland M; Bourke B
    Curr Opin Pulm Med; 2011 Nov; 17(6):461-6. PubMed ID: 21881510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholangiocyte biology and cystic fibrosis liver disease.
    Feranchak AP; Sokol RJ
    Semin Liver Dis; 2001 Nov; 21(4):471-88. PubMed ID: 11745036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.
    Bertolini A; Nguyen M; Zehra SA; Taleb SA; Bauer-Pisani T; Palm N; Strazzabosco M; Fiorotto R
    J Hepatol; 2024 Mar; ():. PubMed ID: 38554847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary complications of cystic fibrosis.
    Feranchak AP
    Curr Gastroenterol Rep; 2004 Jun; 6(3):231-9. PubMed ID: 15128491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology.
    Olivier AK; Gibson-Corley KN; Meyerholz DK
    Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G459-71. PubMed ID: 25591863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
    Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C
    Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.
    Boëlle PY; Debray D; Guillot L; Clement A; Corvol H;
    Hepatology; 2019 Apr; 69(4):1648-1656. PubMed ID: 30058245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver disease in patients with cystic fibrosis.
    Kamal N; Surana P; Koh C
    Curr Opin Gastroenterol; 2018 May; 34(3):146-151. PubMed ID: 29438119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.
    Fiorotto R; Villani A; Kourtidis A; Scirpo R; Amenduni M; Geibel PJ; Cadamuro M; Spirli C; Anastasiadis PZ; Strazzabosco M
    Hepatology; 2016 Dec; 64(6):2118-2134. PubMed ID: 27629435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Manifestations of Cystic Fibrosis.
    Sakiani S; Kleiner DE; Heller T; Koh C
    Clin Liver Dis; 2019 May; 23(2):263-277. PubMed ID: 30947876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
    Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
    Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
    Eidelman O; Srivastava M; Zhang J; Leighton X; Murtie J; Jozwik C; Jacobson K; Weinstein DL; Metcalf EL; Pollard HB
    Mol Med; 2001 Aug; 7(8):523-34. PubMed ID: 11591888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis Liver Disease: Know More.
    Al Sinani S; Al-Mulaabed S; Al Naamani K; Sultan R
    Oman Med J; 2019 Nov; 34(6):482-489. PubMed ID: 31745411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic risk factors for cystic fibrosis-related liver disease in Egyptian CF children: A single-center experience.
    El-Faramawy A; Nasr SZ; Emam MMSA; Fahmy HMH
    Pediatr Pulmonol; 2024 Feb; 59(2):465-471. PubMed ID: 38038166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene.
    Fan Z; Perisse IV; Cotton CU; Regouski M; Meng Q; Domb C; Van Wettere AJ; Wang Z; Harris A; White KL; Polejaeva IA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Root Cause of Cystic Fibrosis.
    Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z
    Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    Dana J; Debray D; Beaufrère A; Hillaire S; Fabre M; Reinhold C; Baumert TF; Berteloot L; Vilgrain V
    J Hepatol; 2022 Feb; 76(2):420-434. PubMed ID: 34678405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.